{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:29:28Z","timestamp":1794410968135,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence exists suggesting tumor-inhibiting properties of deubiquitylase OTUD1 in various malignancies. We herein investigated the anti-tumor effect and clarified the downstream mechanisms of OTUD1 in the chemoresistance of non-small cell lung cancer (NSCLC) cells. Expression of OTUD1 was examined in NSCLC (PC-9 cells) and erlotinib-resistant NSCLC (PC-9\/ER) cell lines. OTUD1 was bioinformatically predicted to be weakly expressed in NSCLC tissue samples and verified in PC-9\/ER cells. PC-9\/ER cells were subsequently subjected to ectopic expression of OTUD1 alone or combined with SOX9 to dissect out the effect of OTUD1 on the proliferation, chemoresistance and apoptosis in vitro and in vivo. OTUD1 upregulation sensitized NSCLC cells to erlotinib both in vitro and in vivo. In the presence of OTUD1 overexpression, nuclear translocation of YAP1 was inhibited and its expression was inactivated. This effect of OTUD1 was associated with the decreased ubiquitination level of YAP1. SOX9\/SPP1 inactivation was the consequence of inhibited nuclear translocation of YAP1. Overexpression of SOX9 reversed the inhibitory effect of OTUD1 on the resistance of NSCLC cells to erlotinib. In conclusion, our study reveals that OTUD1 potentially acts as a tumor suppressor and suppresses erlotinib resistance of NSCLC through the YAP1\/SOX9\/SPP1 axis, suggesting that OTUD1 may serve as a target for reducing chemoresistance for NSCLC.<\/jats:p>","DOI":"10.1038\/s41420-022-01119-w","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T09:07:09Z","timestamp":1664615229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7232-2231","authenticated-orcid":false,"given":"Huafeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"1119_CR1","doi-asserted-by":"publisher","first-page":"390034","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:390034\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1119_CR2","doi-asserted-by":"publisher","first-page":"672612","DOI":"10.3389\/fonc.2021.672612","volume":"11","author":"M Xie","year":"2021","unstructured":"Xie M, Xu X, Fan Y. KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup. Front Oncol. 2021;11:672612.","journal-title":"Front Oncol"},{"key":"1119_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"1119_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl J Med. 2005;353:123\u201332.","journal-title":"N. Engl J Med"},{"key":"1119_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cellsig.2017.02.011","volume":"33","author":"S Piao","year":"2017","unstructured":"Piao S, Pei HZ, Huang B, Baek SH. Ovarian tumor domain-containing protein 1 deubiquitinates and stabilizes p53. Cell Signal. 2017;33:22\u201329.","journal-title":"Cell Signal"},{"key":"1119_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02029-7","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan Y, Xie F, Zhou H, Jin K, Shao L, et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat Commun. 2017;8:2116.","journal-title":"Nat Commun"},{"key":"1119_CR7","doi-asserted-by":"publisher","first-page":"e51162","DOI":"10.15252\/embr.202051162","volume":"22","author":"J Song","year":"2021","unstructured":"Song J, Liu T, Yin Y, Zhao W, Lin Z, Yin Y, et al. The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity. EMBO Rep. 2021;22:e51162.","journal-title":"EMBO Rep"},{"key":"1119_CR8","first-page":"5417","volume":"18","author":"J Deng","year":"2019","unstructured":"Deng J, Hou G, Fang Z, Liu J, Lv XD. Distinct expression and prognostic value of OTU domain-containing proteins in non-small-cell lung cancer. Oncol Lett. 2019;18:5417\u201327.","journal-title":"Oncol Lett"},{"key":"1119_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2021.08.006","volume":"174","author":"M Grattarola","year":"2021","unstructured":"Grattarola M, Cucci MA, Roetto A, Dianzani C, Barrera G, Pizzimenti S. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells. Free Radic Biol Med. 2021;174:202\u201310.","journal-title":"Free Radic Biol Med"},{"key":"1119_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04620-y","volume":"9","author":"F Yao","year":"2018","unstructured":"Yao F, Zhou Z, Kim J, Hang Q, Xiao Z, Ton BN, et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. Nat Commun. 2018;9:2269.","journal-title":"Nat Commun"},{"key":"1119_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/ijc.31561","volume":"143","author":"M Shibata","year":"2018","unstructured":"Shibata M, Ham K, Hoque MO. A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018;143:2133\u201344.","journal-title":"Int J Cancer"},{"key":"1119_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/1759-7714.13280","volume":"11","author":"W He","year":"2020","unstructured":"He W, Zhang Y, Xia S. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p\/YAP1 axis. Thorac Cancer. 2020;11:549\u201360.","journal-title":"Thorac Cancer"},{"key":"1119_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ebiom.2018.01.017","volume":"28","author":"YT Yeung","year":"2018","unstructured":"Yeung YT, Yin S, Lu B, Fan S, Yang R, Bai R, et al. Losmapimod overcomes gefitinib resistance in non-small cell lung cancer by preventing tetraploidization. EBioMedicine. 2018;28:51\u201361.","journal-title":"EBioMedicine"},{"key":"1119_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1541-7786.MCR-19-0895","volume":"18","author":"S Song","year":"2020","unstructured":"Song S, Wang Z, Li Y, Ma L, Jin J, Scott AW, et al. PPARdelta Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res. 2020;18:390\u2013402.","journal-title":"Mol Cancer Res"},{"key":"1119_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1895-2","volume":"17","author":"JQ Huang","year":"2019","unstructured":"Huang JQ, Wei FK, Xu XL, Ye SX, Song JW, Ding PK, et al. SOX9 drives the epithelial-mesenchymal transition in non-small-cell lung cancer through the Wnt\/beta-catenin pathway. J Transl Med. 2019;17:143.","journal-title":"J Transl Med"},{"key":"1119_CR16","doi-asserted-by":"publisher","first-page":"119608","DOI":"10.1016\/j.lfs.2021.119608","volume":"277","author":"SK Tripathi","year":"2021","unstructured":"Tripathi SK, Biswal BK. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting beta-catenin and epithelial to mesenchymal transition in lung cancer. Life Sci. 2021;277:119608.","journal-title":"Life Sci"},{"key":"1119_CR17","doi-asserted-by":"publisher","first-page":"eaat0344","DOI":"10.1126\/scitranslmed.aat0344","volume":"10","author":"C Zhu","year":"2018","unstructured":"Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med. 2018;10:eaat0344.","journal-title":"Sci Transl Med"},{"key":"1119_CR18","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.2147\/OTT.S164007","volume":"11","author":"X Ouyang","year":"2018","unstructured":"Ouyang X, Huang Y, Jin X, Zhao W, Hu T, Wu F, et al. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther. 2018;11:5933\u201341.","journal-title":"Onco Targets Ther"},{"key":"1119_CR19","doi-asserted-by":"publisher","first-page":"2002874","DOI":"10.1002\/advs.202002874","volume":"8","author":"Q Luo","year":"2021","unstructured":"Luo Q, Wu X, Zhao P, Nan Y, Chang W, Zhu X, et al. OTUD1 activates caspase-independent and caspase-dependent apoptosis by promoting AIF nuclear translocation and MCL1 degradation. Adv Sci (Weinh). 2021;8:2002874.","journal-title":"Adv Sci (Weinh)"},{"key":"1119_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cam4.2668","volume":"9","author":"Y Song","year":"2020","unstructured":"Song Y, Sun Y, Lei Y, Yang K, Tang R. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways. Cancer Med. 2020;9:259\u201368.","journal-title":"Cancer Med"},{"key":"1119_CR21","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1038\/s41388-020-1293-5","volume":"39","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang J, Li H, Huang T, Wong CC, Wu F, et al. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Oncogene 2020;39:4375\u201389.","journal-title":"Oncogene"},{"key":"1119_CR22","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41388-018-0476-9","volume":"38","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang Z, Yu X, Huang X, Liu Z, Chai Y, et al. Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma. Oncogene. 2019;38:2042\u201355.","journal-title":"Oncogene"},{"key":"1119_CR23","first-page":"2270","volume":"13","author":"S Liu","year":"2020","unstructured":"Liu S, Li S, Yu X, Wang Q, Sun H. microRNA-133b represses the progression of lung cancer through inhibiting SOX9\/beta-catenin signaling pathway. Int J Clin Exp Pathol. 2020;13:2270\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1119_CR24","doi-asserted-by":"publisher","first-page":"e00307","DOI":"10.1128\/MCB.00307-19","volume":"40","author":"MA Voronkova","year":"2020","unstructured":"Voronkova MA, Rojanasakul LW, Kiratipaiboon C, Rojanasakul Y. The SOX9-Aldehyde dehydrogenase axis determines resistance to chemotherapy in non-small-cell lung cancer. Mol Cell Biol. 2020;40:e00307\u201319.","journal-title":"Mol Cell Biol"},{"key":"1119_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep30489","volume":"6","author":"T Kawai","year":"2016","unstructured":"Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, et al. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep. 2016;6:30489.","journal-title":"Sci Rep"},{"key":"1119_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3727\/096504018X15426271404407","volume":"27","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang F, Yang X, Xue M, Li X, Gao Y, et al. Secreted phosphoprotein 1 (SPP1) contributes to second-generation EGFR tyrosine kinase inhibitor resistance in non-small cell lung cancer. Oncol Res. 2019;27:871\u20137.","journal-title":"Oncol Res"},{"key":"1119_CR27","doi-asserted-by":"publisher","first-page":"dju004","DOI":"10.1093\/jnci\/dju004","volume":"106","author":"H Kadara","year":"2014","unstructured":"Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, et al. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 2014;106:dju004.","journal-title":"J Natl Cancer Inst"},{"key":"1119_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/ijmm.2016.2588","volume":"38","author":"FY Zhao","year":"2016","unstructured":"Zhao FY, Han J, Chen XW, Wang J, Wang XD, Sun JG, et al. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med. 2016;38:183\u201391.","journal-title":"Int J Mol Med"},{"key":"1119_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/CM9.0000000000000823","volume":"133","author":"PF Wu","year":"2020","unstructured":"Wu PF, Gao WW, Sun CL, Ma T, Hao JQ. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer. Chin Med J (Engl). 2020;133:1304\u201311.","journal-title":"Chin Med J (Engl)"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01119-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01119-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01119-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T09:07:14Z","timestamp":1664615234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01119-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01119-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The current study was performed with the approval of the Animal Ethics Committee of Ganzhou People\u2019s Hospital and performed in strict accordance with the Guide for the Care and Use of Laboratory animals published by the US National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"403"}}